Clinical and Biological Remission With Tezepelumab: The Real-World Response in Severe Uncontrolled Asthma.

ABSTRACT:

Introduction

Tezepelumab is an anti-TSLP monoclonal antibody approved for the treatment of severe asthma. It has broad downstream anti-T2 effects, offering the prospect of biological remission. Real-world data on clinical remission rates with tezepelumab is lacking, and the relationship between clinical and biological remission is unclear. Finally, the effectiveness of tezepelumab in patients who have failed to respond to existing biologic therapies is unknown.

Methods

Clinical and biomarker data from adults with severe asthma treated with tezepelumab in a real-world setting was analyzed. Clinical outcome measures including clinical remission were recorded along with rates of biological remission (defined as blood eosinophil count < 300 cells/mcL and FeNO < 25 ppb).

Resul

SUBMITTER: Gates J 

PROVIDER: S-EPMC12186586 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature